FindTrial
Sign In

Appropriate Dosage of Long-acting Insulin at the Time of Artificial Pancreas Withdrawal

Optimal dose of long-acting insulin analogue for withdrawal of artificial pancreas after hepatectomy -pilot study- - Optimal dose of long-acting insulin analogue for withdrawal of artificial pancreas after hepatectomy -pilot study-

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000048787
Enrollment
27
Registered
2022-08-30
Start date
2021-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer, Diabetes

Interventions

None listed

Sponsors

Okayama Saiseikai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A case of partial/ lobectomy of the liver with bedside type artificial pancreas STG-55 (Nikkiso)

Exclusion criteria

Exclusion criteria: Cases of withdrawal from artificial pancreas

Design outcomes

Primary

MeasureTime frame
Approximate formula for determining basal insulin dose at the time of artificial pancreas withdrawal—

Countries

Japan

Contacts

Public ContactToshihisa Tahara

Okayama Saiseikai General Hospital Department of Internal Medicine, Diabetes Center

tt.toshihisa.tahara@gmail.com086-252-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026